by Maria Zannes | Feb 4, 2021 | Press Releases
FEBRUARY 4, 2021 (SAN ANTONIO, TX) China’s leading healthcare company to evaluate bioAffinity’s non-invasive, highly accurate test for early-stage lung cancer with aim to commercialize in world’s largest market Shanghai Fosun Long March Medical Science Co., Ltd....
by Maria Zannes | Nov 10, 2020 | Events, Press Releases
Nov. 10, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that its poster “Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin mediated endocytosis” will...
by Maria Zannes | Oct 22, 2020 | Events, Press Releases
OCTOBER 22, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced its poster “Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity” has been accepted for presentation...
by Maria Zannes | Oct 15, 2020 | Press Releases
Partnership supports patient care and sample collection for automated test demonstrating high accuracy in finding lung cancer FAQ: Answers to Questions about Cypath® Lung October 15, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company,...
by Maria Zannes | Sep 29, 2020 | Press Releases
SEPTEMBER 29, 2020 (San Antonio, TX) FAQ: Answers to Questions about Cypath® Lung bioAffinity Technologies, a privately-held biotech company, today announced Martin Tammemägi, PhD, Professor Emeritus of Health Sciences at Brock University, will serve as Chairman of...
by Maria Zannes | Aug 12, 2020 | Press Releases
Precision Completes Development of CyPath® Lung and Starts CLIA Validation of Cancer Assay for Sale as a Laboratory Developed Test (LDT) FAQ: Answers to Questions about Cypath® Lung August 12, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held biotech...
